Decoding microRNAs in autism spectrum disorder
Molecular Therapy - Nucleic Acids, ISSN: 2162-2531, Vol: 30, Page: 535-546
2022
- 17Citations
- 67Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef3
- Captures67
- Readers67
- 67
- Mentions1
- News Mentions1
- 1
Most Recent News
Qingdao University Researchers Describe Research in miRNA-Based Therapy (Decoding microRNAs in autism spectrum disorder)
2022 DEC 05 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Daily News -- Investigators publish new report on miRNA-based therapy. According
Review Description
Autism spectrum disorder (ASD)—a congenital mental disorder accompanied by social dysfunction and stereotyped behaviors—has attracted a great deal of attention worldwide. A combination of genetic and environmental factors may determine the pathogenesis of ASD. Recent research of multiple ASD models indicates that microRNAs (miRNAs) play a central role at the onset and progression of ASD by repressing the translation of key mRNAs in neural development and functions. As such, miRNAs show great potential to serve as biomarkers for ASD diagnosis or prognosis and therapeutic targets for the treatment of ASD. In this review, we discuss the regulatory mechanisms by which miRNAs influence ASD phenotypes through various in vivo and in vitro models, including necropsy specimens, animal models, cellular models, and, in particular, induced pluripotent stem cells derived from patients with ASD. We then discuss the potential of miRNA-based therapeutic strategies for ASD currently being evaluated in preclinical studies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2162253122002979; http://dx.doi.org/10.1016/j.omtn.2022.11.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142327551&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36457702; https://linkinghub.elsevier.com/retrieve/pii/S2162253122002979; https://dx.doi.org/10.1016/j.omtn.2022.11.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know